October 19, 2021
Dr. Joanne Jiang, Chairman and CEO of LeaderMed Group, hosted a grand opening ceremony in Shanghai and announced the arrival of LeaderMed Group’s, drug development platform in China. In 2021, Chairman Joanne Jiang traveled to many of China’s coastal cities to find high-quality locations for headquarters. After multiple comparisons and considerations, combined with the opinions of the capital side and the comprehensive situation, Shanghai was finally chosen as an important base for Leadermed Group to establish operations.
December 15, 2021
Dr. Jiang and Dr. Yuan from LeaderMed Group recently visited the US headquarters of the world’s top three automatic injection pen medical device companies, to find a suitable auto-injector for LeaderMed Group’s drug-LM008 for diabetes with chronic kidney disease. The drug is expected to become the fourth generation of the world’s leading anti-diabetic weight loss injection, so Lingkang Pharmaceutical Group also equips it with high-quality injection pens as supporting equipment.
January 25, 2022
RNA BIOTECHNOLOGY HAS A BRIGHT FUTURE Dr. Jiang, Chairman of LeaderMed Group, expressed her gratitude to all the guests who visited the event, and described the development plan and future blueprint of LeaderMed Group. After that, Academician Zhao Guoping of the Chinese Academy of Sciences delivered a congratulatory speech, analyzing from the perspectives of microbial genomics and bioinformatics The development trend of the mRNA industry, and encouraged LeaderMed Group to innovate boldly and forge ahead.
June 1, 2022
The Leadermed Health Group Limited (“LeaderMed Group”) announces today that its Founder and Chief Executive Officer, Dr. Joanne Jiang will present at the 2022 Jefferies Healthcare Conference on Friday, 10 June 2022, at 8:30-8:55 AM in TRACK 1.
A live webcast of the presentation will be accessible at https://wsw.com/webcast/jeff240/lmg/1687200. A replay of the presentation will be archived on LeaderMed’s website.
September 14, 2021
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) — LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company focused on diagnostics and pharmaceuticals, announce the formation of a joint venture to develop, manufacture and commercialize two of OPKO’s clinical stage, long-acting drug products in Greater China and eight other Asian territories.
December 7, 2021
In December 2021, Dr. Jiang and Dr. Yuan from LeaderMed Group visited the Princeton University’s Princeton innovation center – Biolabs to learn about the latest biotechnology research and development trends and to connect with the world-class scientific research innovation base. Face-to-face interaction with leaders of European and American cutting-edge biotechnology R&D projects will open up space for LeaderMed Group’s international R&D cooperation, and at the same time promote and enrich pipeline progress.
January 25, 2022
Peptides have been used as medicines for over 70 years. With the development of science and technology and the increase of application, it has become the focus of attention of the pharmaceutical industry. Winzac Capital is an enabling elite investment institution focusing on advanced manufacturing, intelligent IoT, and biomedical fields. It has decisively completed the angel round investment in LeaderMed Health Group Limited, laid out the field of dual-target innovative drugs for diabetes, and helped LeaderMed Group to develop more innovative drugs.
April 26, 2022
LeaderMed Group Expands Pipeline with Aqualung License. Aqualung Therapeutics (“Aqualung”), an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed. The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. Based on strong preclinical results, LeaderMed and Aqualung will collaborate on Multi-Regional Clinical Trials (MRCT) designs for multiple indications including ARDS. The terms of the agreement have not been publicly disclosed but involve customary upfront fees, achievement milestones, and royalties that coincide with commercial sales.